Homing of Tumor-Specific T Cells in the B16OVA/OT-I Model System - towards T Cells as Carriers of Cytotoxic Substances in Therapy of CancermelanomaimmunotherapyuveitisautoimmunityCTLA-4 antibodyCytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expr...
A tumor model was established in C57BL/6J mice via subcutaneous injection of 3×105B16-OVA tumor cells. The effect of alginate/OVA peptide on cell viability was analyzed by use of the CCK-8 assay kit. Activation of macrophages was examined by checking cell surface makers CD40 and CD86 by ...
Figure 2. Tumor growth curve of B16F10 and B16F10-OVA-Luc syngeneic model (n=5). Figure 3. The expression of OVA in tumors by Western Blot. 相关品系 Panc02-OVA-Luc 细胞系名称:Panc02-OVA-Luc 目录号:NMC-230050 MC38-OVA-Luc (2) ...
Figure 2. Tumor growth curve of B16F10 and B16F10-OVA-Luc syngeneic model (n=5). Figure 3. The expression of OVA in tumors by Western Blot. 相关品系 Panc02-OVA-Luc 细胞系名称:Panc02-OVA-Luc 目录号:NMC-230050 MC38-OVA-Luc (2) ...
At a dose of 5 mg/kg/day given before tumor challenge, dasatinib therapy reduced the number of pulmonary metastases. Conversely, a higher dose (25 mg/kg/day), did not affect the number of pulmonary metastases and increased the number of extra-pulmonary metastases. Finally, immunization of ...
895: Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse modeldoi:10.1016/s0959-8049(14)50795-2M. IlanderC. HekimM. Vh-KoskelaP. SavolaS. ThtinenA. HemminkiK. Porkka...
Abstract 2587: Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse modeldoi:10.1016/S0959-8049(14)50795-2M.IlanderC.HekimM.Vähä-KoskelaP.SavolaS.TähtinenSDOSEuropean Journal of Cancer...